
Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.

Your AI-Trained Oncology Knowledge Connection!


Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.

CLND as standard of care for patients with SLN-positive metastatic melanoma is supported by a wealth of compelling prospective data.

Published: October 15th 2016 | Updated:

Published: September 27th 2022 | Updated: